The Leading Community for Trusted Peptide Research & Insights
Research summaries, dosing protocols, and community reports for peptides. Built on clinical data and real-world experiences.
Sexual health peptides work through diverse neuroendocrine pathways. PT-141 (Bremelanotide) is the most notable — it's FDA-approved for hypoactive sexual desire disorder (HSDD) in premenopausal women, making it one of the few peptides with regulatory approval for a sexual health indication.
Other peptides in this space include Kisspeptin (a key regulator of the reproductive axis), Oxytocin (the "bonding hormone"), and Gonadorelin (a GnRH agonist used to support testosterone production during hormonal therapies).
Yes. PT-141 (Bremelanotide), marketed as Vyleesi, is FDA-approved for hypoactive sexual desire disorder (HSDD) in premenopausal women. It works by activating melanocortin-4 receptors in the brain, which differs from the vascular mechanism of PDE5 inhibitors like Viagra.
PT-141 works centrally in the brain through melanocortin receptors to increase sexual desire, while Viagra (sildenafil) works peripherally by increasing blood flow through PDE5 inhibition. PT-141 affects desire/arousal at the neurological level; Viagra affects the physical mechanics of erection.
Kisspeptin stimulates GnRH release from the hypothalamus, which triggers LH and FSH release from the pituitary, ultimately stimulating testosterone production. Clinical studies have shown acute kisspeptin administration increases testosterone levels. It's being researched as a potential diagnostic and therapeutic tool for reproductive disorders.